fucoxanthin and Atrophy

fucoxanthin has been researched along with Atrophy* in 1 studies

Other Studies

1 other study(ies) available for fucoxanthin and Atrophy

ArticleYear
Fucoxanthin rescues dexamethasone induced C2C12 myotubes atrophy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 139

    Muscle atrophy and weakness are the adverse effects of long-term or high dose usage of glucocorticoids. In the present study, we explored the effects of fucoxanthin (10 μM) on dexamethasone (10 μM)-induced atrophy in C2C12 myotubes and investigated its underlying mechanisms. The diameter of myotubes was observed under a light microscope, and the expression of myosin heavy chain (MyHC), proteolysis-related, autophagy-related, apoptosis-related, and mitochondria-related proteins was analyzed by western blots or immunoprecipitation. Fucoxanthin alleviates dexamethasone-induced muscle atrophy in C2C12 myotubes, indicated by increased myotubes diameter and expression of MyHC, decreased expression of muscle atrophy F-box (Atrogin-1) and muscle ring finger 1 (MuRF1). Through activating SIRT1, fucoxanthin inhibits forkhead box O (FoxO) transcriptional activity to reduce protein degradation, induces autophagy to enhance degraded protein clearance, promotes mitochondrial function and diminishes apoptosis. In conclusion, we identified fucoxanthin ameliorates dexamethasone induced C2C12 myotubes atrophy through SIRT1 activation.

    Topics: Animals; Apoptosis; Atrophy; Autophagy; Cell Line; Cell Survival; Dexamethasone; Forkhead Box Protein O3; Mice; Muscle Fibers, Skeletal; Proto-Oncogene Proteins c-akt; Sirtuin 1; Xanthophylls

2021